Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance [Phase 3]
Phase 3 trial update in AML patients with FLT3 mutations evaluating peripheral blast clearance.
-
FDA approval · 2022-02-28FDA Approved: CYTARABINE — Original Application (Meitheal Pharmaceuticals Inc.)
The FDA approves Meitheal Pharmaceuticals' original application for CYTARABINE (cytarabine) as a generic injectable product, enabling its ma…
-
CLINICAL_TRIALS trial_result · 2022-02-23Clinical Trial Update: Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]
A Phase 1/2 study evaluating liposomal annamycin for acute myeloid leukemia has completed with results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-02-21Clinical Trial Update: GRASPA Treatment for Patients With Acute Myeloblastic Leukemia [Phase 2]
Phase 2 trial update for GRASPA in patients with Acute Myeloid Leukemia; results have been posted.
-
CLINICAL_TRIALS trial_result · 2022-02-21Clinical Trial Update: A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia [Phase 1]
Phase 1 trial evaluating safety and pharmacokinetics of atezolizumab with Hu5F9-G4 in relapsed/refractory acute myeloid leukemia; study term…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-02-09Clinical Trial Update: Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome [Phase 1, Phase 2]
A phase 1/2 trial evaluating vosaroxin with decitabine in older adults with acute myeloid leukemia and high-risk myelodysplastic syndrome ha…
-
FDA approval · 2022-01-27FDA Approved: IDARUBICIN HYDROCHLORIDE — Supplemental Application (Meitheal Pharmaceuticals Inc.)
The FDA approved a supplemental application for idarubicin hydrochloride filed by Meitheal Pharmaceuticals Inc. This action completes the su…
-
CLINICAL_TRIALS trial_result · 2022-01-25Clinical Trial Update: PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant [Phase 2]
Phase 2 clinical trial update for PF-04449913 in adults with acute myeloid leukemia at high risk of relapse after donor stem cell transplant…
-
FDA approval · 2022-01-21FDA Approved: BUSULFAN — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Busulfan by Amneal Pharmaceuticals LLC, updating the approval for this generic product.
-
CLINICAL_TRIALS trial_result · 2022-01-19Clinical Trial Update: Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma [Phase 1, Phase 2]
A phase 1/2 clinical trial of CAR T-cell therapy for acute myeloid leukemia and multiple myeloma has terminated with results posted in 2022.
-
FDA approval · 2022-01-12FDA Approved: XOSPATA — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for XOSPATA (gilteritinib) submitted by Astellas Pharma US, Inc.
-
CLINICAL_TRIALS trial_result · 2022-01-03Clinical Trial Update: Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial evaluating azacitidine with or without ATRA in newly diagnosed unfit acute myeloid leukemia or intermediate…
-
CLINICAL_TRIALS trial_result · 2021-12-30Clinical Trial Update: Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]
An update on an anti-FLT3 CAR T-cell therapy being evaluated in FLT3-positive relapsed/refractory acute myeloid leukemia across Phase 1 and …
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes [Phase 2]
Phase 2 clinical trial evaluating bemcentinib for myelodysplastic syndromes and related conditions has completed.
-
CLINICAL_TRIALS trial_result · 2021-12-16Clinical Trial Update: Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) [Phase 3]
Phase 3 trial evaluating fludarabine-IV busulfan with or without clofarabine as conditioning for allogeneic hematopoietic stem cell transpla…
-
CLINICAL_TRIALS trial_result · 2021-12-08Clinical Trial Update: Vitamin D Effect on A Disintegrin-like And Metalloprotease Thrombospondin1 Motif 13& Interleukin 6 in Leukemia [Phase 1, Phase 2]
Phase 1/2 trial exploring vitamin D effects on ADAMTS13 and interleukin-6 pathways in acute myeloid leukemia with vitamin D deficiency; stud…
-
CLINICAL_TRIALS trial_result · 2021-12-03Clinical Trial Update: PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML [Phase 3]
A Phase 3 trial evaluating a PD-1 inhibitor combined with azacytidine, homoharringtonine, cytarabine, and G-CSF for refractory or relapsed a…
-
CLINICAL_TRIALS trial_result · 2021-12-02Clinical Trial Update: JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]
Phase 2 clinical trial of JNJ-40346527 in relapsed or refractory acute myeloid leukemia has terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2021-12-01Clinical Trial Update: Double Cord Versus Haploidentical (BMT CTN 1101) [Phase 3]
Phase 3 trial comparing double cord blood transplantation versus haploidentical transplant in acute leukemias completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-11-19Clinical Trial Update: Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) [Phase 3]
Phase 3 trial POLO-AML-2 evaluated volasertib plus low-dose cytarabine in patients 65+ with untreated acute myeloid leukemia ineligible for …
-
CLINICAL_TRIALS trial_result · 2021-11-15Clinical Trial Update: Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza) [Phase 2]
Phase 2 trial investigating azacitidine (Vidaza) for patients with myelodysplastic syndrome or acute myeloid leukemia at impending hematolog…
-
CLINICAL_TRIALS trial_result · 2021-11-15Clinical Trial Update: Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features [Phase 2]
Phase 2 trial evaluating individualized induction therapy for non-elderly adults with adverse-risk acute myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2021-11-02Clinical Trial Update: A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated [Phase 3]
A Phase 3 trial comparing SKLB1028 to salvage chemotherapy in relapsed/refractory FLT3-mutated acute myeloid leukemia is ongoing with status…
-
CLINICAL_TRIALS trial_result · 2021-11-02Clinical Trial Update: A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS) [Phase 2]
A Phase 2 dose-confirmation study of oral clofarabine in adults previously treated for myelodysplastic syndromes (MDS) has completed; result…
-
CLINICAL_TRIALS trial_result · 2021-11-01Clinical Trial Update: Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm [Phase 2]
Phase 2 trial evaluating higher or lower doses of cladribine, cytarabine, and mitoxantrone in medically less fit patients with newly diagnos…